Severe asthma and the omalizumab option

@article{Miller2008SevereAA,
  title={Severe asthma and the omalizumab option},
  author={Christopher W T Miller and Narayanaswamy Krishnaswamy and Chambless R Johnston and G. Krishnaswamy},
  journal={Clinical and molecular allergy : CMA},
  year={2008},
  volume={6},
  pages={4 - 4}
}
Atopic diseases and asthma are increasing at a remarkable rate on a global scale. It is now well recognized that asthma is a chronic inflammatory disease of the airways. The inflammatory process in many patients is driven by an immunoglobulin E (IgE)-dependent process. Mast cell activation and release of mediators, in response to allergen and IgE, results in a cascade response, culminating in B lymphocyte, T lymphocyte, eosinophil, fibroblast, smooth muscle cell and endothelial activation. This… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 100 references

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.

The Journal of allergy and clinical immunology • 2005
View 12 Excerpts
Highly Influenced

The pharmacological basis of anti-IgE therapy

Nature Biotechnology • 2000
View 9 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…